圣湘生物科技股份有限公司 章程 （2025 年第三次临时股东会审议通过） 二〇二五年七月 第一章总则 第一条 为维护圣湘生物科技股份有限公司（以下简称"公司"）、股东、 职工和债权人的合法权益，规范公司的组织和行为，根据《中华人民共和国公 司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证 券法》"）和其他有关规定，制订本章程。 第二条 公司系依照《公司法》、《中华人民共和国市场主体登记管理条 例》和其他有关规定成立的股份有限公司。公司由湖南圣湘生物科技有限公司 整体变更发起设立，在长沙市市场监督管理局注册登记，取得营业执照, 统一 社会信用代码为 91430100673566826X。 第三条 公司于 2020 年 7 月 28 日经中国证券监督管理委员会 第六条 公司注册资本为人民币 579,388,006 元。 第七条 公司为永久存续的股份有限公司。 第八条 代表公司执行公司事务的董事为公司法定代表人。董事长为代表 公司执行事务的董事。担任法定代表人的董事或者经理辞任的，视为同时辞去 法定代表人。法定代表人辞任的，公司将在法定代表人辞任之日起三十日内确 定新的法定代表人。 法定代 ...

第二章 关联人和关联交易 第三条 公司关联人（关联方），指具有下列情形之一的自然人、法人或 其他组织： （一）直接或者间接控制公司的自然人、法人或其他组织； 圣湘生物科技股份有限公司 关联交易管理制度 第一章 总 则 第一条 为保证圣湘生物科技股份有限公司（以下简称：公司或本公司） 关联交易的公允性，保证公司各项业务通过必要的关联交易顺利地开展，规范公 司关联交易管理体系的建立，确保公司的关联交易行为不损害公司、公司债权人 和全体股东的利益，特别是中小投资者的合法权益，保证公司与关联人之间订立 的关联交易合同符合公平、公开、公允的原则，根据《中华人民共和国公司法》、 《中华人民共和国证券法》、《上海证券交易所科创板股票上市规则》（以下简 称"《股票上市规则》"）等有关法律、法规，以及《公司章程》的规定，结合本 公司生产、经营的实际情况制定本制度。 第二条 公司发生关联交易，应当保证关联交易的合法性、必要性、合理 性和公允性，保持公司的独立性，不得利用关联交易输送利益或调节财务指标， 损害公司利益，不得以任何方式隐瞒关联关系。公司关联交易应当依照有关规定 严格履行决策程序和信息披露义务。 （三）公司董事、高级管 ...

General Principles - The rules are established to regulate company behavior and ensure shareholders can exercise their rights according to relevant laws and regulations [1][2] - The company must hold shareholder meetings in strict accordance with laws, regulations, and its articles of association [1][2] Types of Shareholder Meetings - Shareholder meetings are categorized into annual and extraordinary meetings, with annual meetings held within six months after the end of the previous fiscal year [1] - Extraordinary meetings must be convened within two months under specific circumstances, such as insufficient board members or significant losses [1] Convening Shareholder Meetings - The board of directors is responsible for convening meetings within the stipulated time frame [3][4] - Independent directors can propose extraordinary meetings, and the board must respond within ten days [3][4] - Shareholders holding more than 10% of shares can request extraordinary meetings, and the board must provide feedback within ten days [4][5] Proposals and Notifications - Proposals must fall within the scope of shareholder meeting authority and comply with legal requirements [6][7] - Shareholders holding at least 1% of shares can submit proposals ten days before the meeting [6][7] - Notifications for annual meetings must be sent 20 days in advance, while extraordinary meetings require 15 days' notice [7] Meeting Procedures - Meetings should be held at the company's registered address or a specified location, and can also utilize electronic communication methods [9][19] - Shareholders must present valid identification to attend meetings, and proxies must have written authorization [10][11] Voting and Decision-Making - Voting can be conducted through various methods, including electronic means, and results must be announced immediately [14][40] - The board must ensure that the meeting proceeds smoothly and address any disruptions [20][21] - Related shareholders must abstain from voting on matters where they have a conflict of interest [12][13] Record Keeping and Compliance - Meeting records must include details such as time, location, attendees, and voting results, and must be preserved for at least ten years [42][43] - Any resolutions passed must comply with legal standards, and disputes regarding the validity of resolutions can be taken to court [46][47] Implementation and Interpretation - The rules take effect upon approval by the shareholder meeting and are subject to interpretation by the board of directors [49][50]

Core Viewpoint - The legal opinion letter from Hunan Qiyuan Law Firm confirms that Shengxiang Biotechnology Co., Ltd. is eligible to implement its 2025 restricted stock incentive plan, having complied with relevant laws and regulations [1][2][6]. Group 1: Company Background - Shengxiang Biotechnology was established by the transformation of Hunan Shengxiang Biotechnology Co., Ltd. and was officially registered on August 30, 2019 [4]. - The company received approval from the China Securities Regulatory Commission for its initial public offering, issuing 40 million shares on August 8, 2020, and is listed on the Shanghai Stock Exchange under the stock code 688289 [4]. Group 2: Legal Compliance - The law firm has verified that the company meets all legal requirements to proceed with the incentive plan, including the absence of any conditions that would necessitate termination or suspension of the plan [6][10]. - The firm has confirmed that the company has provided all necessary documentation and that there are no significant omissions or misrepresentations [2][3]. Group 3: Incentive Plan Details - The 2025 restricted stock incentive plan was approved by the company's board on July 10, 2025, and includes provisions for the purpose, management, and distribution of rights among the incentive recipients [7][10]. - The plan specifies that the funding for the incentive will come from the participants' own resources, with the company not providing any financial assistance [12]. Group 4: Impact on Stakeholders - The board's remuneration and assessment committee has indicated that the incentive plan is beneficial for the company's sustainable development and does not harm the interests of the company or its shareholders [12][13]. - The incentive plan's implementation is contingent upon further legal procedures and approval from the shareholders' meeting [9][14].

Core Viewpoint - The report serves as an independent financial advisory opinion on the 2025 Restricted Stock Incentive Plan of Shengxiang Biotechnology Co., Ltd, ensuring compliance with relevant laws and regulations while assessing the plan's feasibility and potential impact on the company's sustainable development and shareholder interests [1][2][18]. Group 1: Independent Financial Advisor's Role - The independent financial advisor, Shanghai Miaodao Enterprise Management Consulting Co., Ltd, was commissioned to provide an advisory report based on the 2025 Restricted Stock Incentive Plan [1]. - The advisor conducted due diligence and confirmed that the professional opinions expressed align with the disclosed documents of the company [2][3]. Group 2: Incentive Plan Overview - The incentive plan involves granting 1,192,600 restricted stocks, accounting for approximately 0.21% of the company's total share capital of 579,388,006 shares [5][6]. - The plan is designed to motivate key employees of the wholly-owned subsidiary, Zhongshan Shengxiang Haiji Biotechnology Co., Ltd, and is structured to align the interests of the company, shareholders, and core team members [23]. Group 3: Conditions and Terms - The grant price for the restricted stocks is set at 16.40 RMB per share, which is 79.46% of the average trading price on the day before the plan was announced [10][11]. - The plan includes specific performance targets for the subsidiary, with net profit goals of no less than 140 million RMB for 2025 and 180 million RMB for 2026 [12][16]. Group 4: Compliance and Feasibility - The plan complies with the relevant regulations, including the Management Measures and the Self-Regulatory Guidelines, ensuring that the granting conditions and procedures are legally sound [18][19]. - The independent financial advisor confirmed that the plan's implementation would positively impact the company's sustainable operations and shareholder equity [23][24]. Group 5: Performance Evaluation - The performance evaluation system for the incentive plan includes both company-level and individual-level assessments, ensuring a comprehensive evaluation of the employees' contributions [26]. - The plan's structure is designed to motivate employees while ensuring that the interests of shareholders are not compromised [25][26].

Core Viewpoint - The company is implementing a new stock incentive plan aimed at enhancing corporate governance, attracting and retaining key employees, and aligning the interests of shareholders, the company, and the core team for long-term development. Group 1: Purpose of the Incentive Plan - The incentive plan aims to improve corporate governance and establish a long-term incentive mechanism to attract and retain core employees of the wholly-owned subsidiary, Zhongshan Haiji [1][2] - The plan is designed to enhance the cohesion of the core team and the company's core competitiveness, ensuring the achievement of strategic and operational goals while safeguarding shareholder interests [1][2] Group 2: Details of the Incentive Plan - The plan involves granting 1,192,600 restricted stocks, accounting for approximately 0.21% of the company's total share capital of 57,938,800.06 shares [5][6] - The stock will be sourced from either newly issued A-shares or repurchased shares from the secondary market [5][6] Group 3: Eligibility and Distribution - The incentive plan targets 9 core employees from Zhongshan Haiji, representing 0.38% of the total workforce of 2,346 employees [7][9] - The plan excludes independent directors, supervisors, and major shareholders or their immediate family members [7][9] Group 4: Vesting Conditions - The restricted stocks will vest in three phases, with the first vesting occurring 12 months after the grant date, and subsequent vesting contingent on meeting performance targets [10][12] - Performance targets include achieving a net profit of no less than 140 million yuan in 2025 and 180 million yuan in 2026 for Zhongshan Haiji [18][20] Group 5: Grant Price and Valuation - The grant price for the restricted stocks is set at 16.40 yuan per share, which is 80% of the closing price on the day the plan was reviewed by the board [13][14] - The total estimated cost of the stock incentive plan is projected to be 5.9057 million yuan, which will be recognized as an expense over the vesting period [26][29] Group 6: Rights and Obligations - The company is responsible for verifying the eligibility of the incentive recipients and ensuring compliance with the vesting conditions [30][31] - Recipients must contribute to the company's development and cannot transfer or use the stocks as collateral until they are vested [30][31]

证券代码：688289 证券简称：圣湘生物 公告编号：2025-043 圣湘生物科技股份有限公司 2025 年限制性股票激励计划（草案） 摘要公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 股权激励方式：第二类限制性股票。 股份来源：圣湘生物科技股份有限公司（以下简称"圣湘生物""本公 司""公司"或"上市公司"）向激励对象定向发行的本公司人民币 A 股普通 股股票或从二级市场回购的本公司人民币 A 股普通股股票。 截至本激励计划草案公告日，公司同时正在实施公司 2021 年限制性股票激 励计划、公司 2023 年限制性股票激励计划和公司 2023 年第二期限制性股票激励 计划。本激励计划与公司 2021 年限制性股票激励计划、公司 2023 年限制性股票 激励计划及公司 2023 年第二期限制性股票激励计划相互独立，不存在相关联系。 股权激励的权益总数及涉及的标的股票总数：圣湘生物 2025 年限制性股票 激励计划（以下简称"本激励计划"）拟授予激励对象的限制性股票数量为 119.2600 万股，约 ...

圣湘生物科技股份有限公司 2025 年限制性股票激励计划激励对象名单 圣湘生物科技股份有限公司 董事会 2025 年 7 月 10 日 1 注： 1、公司全部在有效期内的股权激励计划所涉及的标的股票总数累计未超过公司股本总额的 20%。上述任何一名激励对象通过全部在有效期内的股权激励计划获授的本公司股票均累计未超 过公司股本总额的 1%。 2、本激励计划涉及的激励对象不包括公司独立董事、监事、单独或合计持有公司 5%以上股 份的股东或实际控制人及其配偶、父母、子女以及外籍员工。 圣湘生物科技股份有限公司 2025 年限制性股票激励计划激励对象名单 | 职务 | 获授的限制 | 占本激励计划 | 占本激励计划 | | --- | --- | --- | --- | | | 性股票数量 | 拟授出权益数 | 草案公布日股 | | | （万股） | 量的比例 | 本总额的比例 | | 公司全资子公司中山圣湘海济生物医药有 限公司的核心骨干员工 | 119.26 | 100.00% | 0.21% | | 合计 | 119.26 | 100.00% | 0.21% | ...

圣湘生物科技股份有限公司 2025 年限制性股票激励计划（草案） 证券简称：圣湘生物 证券代码：688289 圣湘生物科技股份有限公司 2025 年限制性股票激励计划（草案） 二〇二五年七月 圣湘生物科技股份有限公司 2025 年限制性股票激励计划（草案） 声明 本公司及全体董事、监事保证本激励计划及其摘要不存在任何虚假记载、误 导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责 任。 1 圣湘生物科技股份有限公司 2025 年限制性股票激励计划（草案） 特别提示 一、《圣湘生物科技股份有限公司 2025 年限制性股票激励计划（草案）》 由圣湘生物科技股份有限公司（以下简称"圣湘生物""公司"或"本公司"） 依据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司股权激励 管理办法》《上海证券交易所科创板股票上市规则》《科创板上市公司自律监管 指南第 4 号——股权激励信息披露》和其他有关法律、行政法规、规范性文件， 以及《公司章程》等有关规定制订。 二、圣湘生物 2025 年限制性股票激励计划（以下简称"本激励计划"）采 取的激励形式为第二类限制性股票。股票来源为公司向激励对象定向 ...

上海妙道企业管理咨询有限公司 关于 圣湘生物科技股份有限公司 2025 年限制性股票激励计划（草案） 之 独立财务顾问报告 独立财务顾问： 二〇二五年七月 | ਮ | | --- | | 第一章 | 声 明 3 | | --- | --- | | 第二章 | 释 义 5 | | 第三章 | 基本假设 6 | | 第四章 | 本激励计划的主要内容 7 | | 一、本激励计划拟授出的权益形式及涉及的标的股票来源及种类 7 | | | 二、拟授出权益的数量及占公司股份总额的比例 7 | | | 三、本激励计划的有效期、授予日、归属安排和禁售期 7 | | | 四、限制性股票的授予价格及确定方法 9 | | | 五、限制性股票的授予与归属条件 10 | | | 六、本激励计划的其他内容 14 | | | 第五章 | 本次独立财务顾问意见 15 | | 一、对本激励计划是否符合政策法规规定的核查意见 15 | | | 二、对圣湘生物实行本激励计划可行性的核查意见 15 | | | 三、对激励对象范围和资格的核查意见 16 | | | 四、对本激励计划的权益授出额度的核查意见 17 | | | 五、对公司实施本激励计划的 ...